This chapter presents a series of case studies with multiple choice questions and answers that focus on the pitfalls in the diagnosis of non-Hodgkin's lymphomas. It commences with a discourse on the diagnosis B-cell lymphomas. A subset of aggressive and high grade B-cell lymphomas that feature characteristics intermediate between those of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) are grouped together under the designation BCLU-DLBCL/BL. The chapter discusses the diagnosis of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL). It also focuses on the diagnosis of primary mediastinal (thymic) large B-cell lymphoma T-lymphoblastic leukemia/lymphoma, pediatric follicular lymphoma, and cyclin D1-negative mantle cell ly...
Fine needle sampling is a fast, safe, and potentially cost-effective method of obtaining tissue for ...
Lymphoma diagnosis integrates clinical, morphological, immunophenotypical, and molecular genetic fea...
Hodgkin lymphoma accounts for approximately 15% of all lymphomas. The World Health Organization 2017...
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tu...
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tu...
Objectives: Intermediate-to-large B-cell lymphomas represent a heterogeneous group of aggressive les...
The 2016 revised World Health Organization (WHO) classification includes several provisional borderl...
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) represents approximately 5% of Hodgkin lymph...
Background: Although the WHO classification (2001) requires a great deal of morphologic, immunopheno...
Lymphomas are a heterogeneous group of diseases with various histological signs which are different ...
Despite advances in immunohistochemistry and molecular biology, the distinction between classical Ho...
<p>DLBCL indicates diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; new, a diagnosis of lym...
Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphoid tumour world-wide. This cate...
Bone marrow (BM) examinations are carried out as a cornerstone procedure for diagnosis, staging and ...
Some of the limitations of fine needle aspiration (FNA) in the cytodiagnosis of lymphoma include pro...
Fine needle sampling is a fast, safe, and potentially cost-effective method of obtaining tissue for ...
Lymphoma diagnosis integrates clinical, morphological, immunophenotypical, and molecular genetic fea...
Hodgkin lymphoma accounts for approximately 15% of all lymphomas. The World Health Organization 2017...
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tu...
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tu...
Objectives: Intermediate-to-large B-cell lymphomas represent a heterogeneous group of aggressive les...
The 2016 revised World Health Organization (WHO) classification includes several provisional borderl...
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) represents approximately 5% of Hodgkin lymph...
Background: Although the WHO classification (2001) requires a great deal of morphologic, immunopheno...
Lymphomas are a heterogeneous group of diseases with various histological signs which are different ...
Despite advances in immunohistochemistry and molecular biology, the distinction between classical Ho...
<p>DLBCL indicates diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; new, a diagnosis of lym...
Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphoid tumour world-wide. This cate...
Bone marrow (BM) examinations are carried out as a cornerstone procedure for diagnosis, staging and ...
Some of the limitations of fine needle aspiration (FNA) in the cytodiagnosis of lymphoma include pro...
Fine needle sampling is a fast, safe, and potentially cost-effective method of obtaining tissue for ...
Lymphoma diagnosis integrates clinical, morphological, immunophenotypical, and molecular genetic fea...
Hodgkin lymphoma accounts for approximately 15% of all lymphomas. The World Health Organization 2017...